A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 - Oh, D Y; He, A R; Qin, S (J Clin Oncol, 2022)
(4, suppl):